Table 2.
Change in Predose Permanent Product Measure of Performance Scores by Time Point for Double-Blind Phase (Full Analysis Set)
| Time postdose (hours) | Change from predose score, mean (SD) |
LS mean differencea | 95% CI | p | |
|---|---|---|---|---|---|
| d-ATS (N = 106) | Placebo (N = 106) | ||||
| No. attempted | |||||
| 1 | 17.5 (34.8) | −9.2 (33.0) | 10.3 | −6.6 to 27.2 | 0.231 |
| 2 | 34.4 (42.2) | −19.5 (38.0) | 36.4 | 19.5 to 53.2 | <0.001 |
| 3 | 35.7 (44.8) | −28.2 (43.7) | 46.6 | 29.7 to 63.4 | <0.001 |
| 4.5 | 35.6 (43.0) | −25.2 (37.9) | 43.1 | 26.2 to 59.9 | <0.001 |
| 6 | 33.5 (43.4) | −29.0 (47.0) | 45.2 | 28.4 to 62.1 | <0.001 |
| 7 | 34.1 (45.3) | −27.0 (39.3) | 43.5 | 26.6 to 60.4 | <0.001 |
| 9 | 32.2 (46.3) | −18.8 (36.4) | 34.9 | 18.0 to 51.8 | <0.001 |
| 10 | 24.9 (52.6) | −23.7 (43.8) | 32.5 | 15.6 to 49.4 | <0.001 |
| 12 | 28.0 (48.6) | −25.7 (43.4) | 37.3 | 20.4 to 54.2 | <0.001 |
| No. correct | |||||
| 1 | 17.3 (34.2) | −9.4 (32.7) | 10.9 | −5.9 to 27.7 | 0.204 |
| 2 | 33.9 (42.0) | −19.0 (37.5) | 36.0 | 19.2 to 52.8 | <0.001 |
| 3 | 35.2 (44.9) | −29.0 (40.8) | 47.5 | 30.8 to 64.3 | <0.001 |
| 4.5 | 35.5 (42.9) | −25.3 (37.8) | 43.6 | 26.8 to 60.3 | <0.001 |
| 6 | 33.6 (42.8) | −28.5 (46.1) | 45.4 | 28.6 to 62.2 | <0.001 |
| 7 | 33.7 (45.2) | −26.9 (38.9) | 43.5 | 26.7 to 60.4 | <0.001 |
| 9 | 31.8 (45.6) | −19.7 (35.0) | 36.1 | 19.2 to 52.9 | <0.001 |
| 10 | 25.0 (51.0) | −24.0 (42.1) | 33.5 | 16.6 to 50.3 | <0.001 |
| 12 | 28.2 (47.4) | −26.5 (42.1) | 38.9 | 22.0 to 55.7 | <0.001 |
a
Difference does not equal to that of the mean for d-ATS versus placebo, as those are mean values rather than LS mean values.
CI, confidence interval; d-ATS, dextroamphetamine transdermal system; LS, least squares.